Inferensys

Glossary

FDA Predetermined Change Control Plan (PCCP)

A regulatory mechanism allowing manufacturers of AI/ML-enabled medical devices to pre-specify planned modifications without requiring a new marketing submission.
Modern WeWork hardware lab area with product team collaborating around AI device prototypes, 3D printer in background, dramatic industrial lighting with product sketches on glass walls.
REGULATORY MECHANISM

What is FDA Predetermined Change Control Plan (PCCP)?

A regulatory mechanism allowing manufacturers of AI/ML-enabled medical devices to pre-specify planned modifications without requiring a new marketing submission.

A Predetermined Change Control Plan (PCCP) is a regulatory mechanism established by the FDA that allows manufacturers of AI/ML-enabled medical devices to prospectively define and seek pre-authorization for planned modifications to their software. This framework acknowledges the iterative nature of machine learning, enabling a device to evolve and improve within a pre-specified boundary of safe operation without triggering a new 510(k) or PMA submission for each update.

A PCCP submission must detail the specific planned changes, the protocol for implementing those changes, and the rigorous verification and validation testing to demonstrate continued safety and effectiveness. By shifting the regulatory focus from the static product to the manufacturer's quality system and change management process, the PCCP reduces the administrative burden of continuous learning while maintaining a high standard of patient safety and device integrity.

REGULATORY ARCHITECTURE

Key Components of a PCCP

A Predetermined Change Control Plan (PCCP) is a structured regulatory submission that allows manufacturers of AI/ML-enabled medical devices to pre-specify planned modifications without requiring a new 510(k) or PMA supplement. The following components define its core architecture.

01

Description of Modifications

A detailed, granular specification of the planned changes the manufacturer intends to implement post-market. This section must define the scope and nature of modifications—whether they involve retraining the model on new data, expanding the input data types, or adjusting the model architecture. Each modification must be described with sufficient technical detail to allow FDA reviewers to assess its impact on safety and effectiveness. The description must distinguish between locked algorithms (fixed after training) and adaptive algorithms (continuously learning).

Pre-Specified
Regulatory Posture
02

Modification Protocol

The step-by-step methodology the manufacturer will follow when implementing the pre-specified changes. This protocol functions as a binding standard operating procedure, detailing:

  • Data management practices: How new training data is collected, curated, and validated
  • Verification activities: Specific tests to confirm the modification was implemented correctly
  • Validation activities: Performance benchmarks that must be met before the modified device is released
  • Acceptance criteria: Quantitative thresholds for accuracy, sensitivity, and specificity that gate deployment
SOP
Binding Procedure
03

Impact Assessment

A rigorous, prospective analysis of the benefits and risks introduced by the planned modifications. This section must evaluate how changes could affect:

  • Device performance: Impact on sensitivity, specificity, and predictive values across subpopulations
  • Clinical workflow: How the modified output alters clinician decision-making
  • Safety profile: Potential for new or increased harms, including misdiagnosis or delayed treatment The assessment must demonstrate that the benefit-risk profile remains favorable after each modification, with specific attention to health equity and performance across demographic groups.
Benefit-Risk
Evaluation Framework
04

SOTA Update Process

The SOTA (State of the Art) Update Process defines how the manufacturer will ensure the modified device remains consistent with current scientific consensus and technological standards. This component requires:

  • A literature monitoring plan to track emerging clinical evidence
  • Comparator benchmarking against contemporary diagnostic standards
  • A commitment to update the device's reference standard when the clinical community adopts new diagnostic criteria This process prevents algorithmic drift where the device becomes clinically obsolete while remaining statistically stable.
05

Transparency & Labeling

A comprehensive plan for communicating modifications to end-users, patients, and the FDA. This component specifies:

  • Version control documentation: Clear labeling of model versions with release notes detailing what changed
  • User notification mechanisms: How clinicians are informed of updates before they encounter modified outputs
  • Public summary: A plain-language description of modifications for patient-facing transparency
  • Performance reporting: Updated performance characteristics published with each modification cycle The goal is to maintain informed trust in the device's evolving capabilities.
Continuous
Disclosure Cadence
REGULATORY CLARITY

Frequently Asked Questions

Clear, technically precise answers to the most common questions about the FDA's Predetermined Change Control Plan for AI/ML-enabled medical devices.

An FDA Predetermined Change Control Plan (PCCP) is a regulatory mechanism that allows manufacturers of AI/ML-enabled medical devices (specifically Software as a Medical Device, or SaMD) to pre-specify and seek pre-authorization for planned future modifications without requiring a new 510(k) or De Novo marketing submission for each update. The PCCP is reviewed and authorized as part of the initial device clearance. It consists of two core components: the Description of Modifications, which details what specific changes will be made (e.g., expanding input data types, retraining on new populations), and the Modification Protocol, which describes how those changes will be developed, validated, and implemented while maintaining safety and effectiveness. This framework acknowledges the iterative nature of machine learning and shifts the regulatory focus from the static artifact to the manufacturer's quality system and change management rigor.

Prasad Kumkar

About the author

Prasad Kumkar

CEO & MD, Inference Systems

Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.

His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.